Patient-Reported Outcomes, Patient-Reported Information by Mike Baldwin et al.
Patient-Reported Outcomes,
Patient-Reported Information
From Randomized Controlled Trials to the Social Web and Beyond
Mike Baldwin,1 Andrew Spong,2 Lynda Doward3 and Ari Gnanasakthy4
1 Novartis Horsham Research Centre, Horsham, West Sussex, UK
2 Nexus, London, UK
3 Galen Research Ltd, Manchester, UK
4 Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA
Abstract Internet communication is developing. Social networking sites enable
patients to publish and receive communications very easily. Many stake-
holders, including patients, are using these media to find new ways to make
sense of diseases, to find and discuss treatments, and to give support to
patients and their caregivers. We argue for a new definition of patient-reported
information (PRI), which differs from the usual patient-reported outcomes
(PRO). These new emergent data from the social web have important im-
plications for decision making, at both an individual and a population level.
We discuss new emergent technologies that will help aggregate this in-
formation and discuss how this will be assessed alongside the use of PROs in
randomized controlled trials and how these new emergent data will be one
facet of changing the relationship between the various stakeholders in
achieving better co-created health.
The role of the patient in the healthcare decision-
making process has becomemore prominent over
the last decade. Patients are increasingly regarded
as one of the key stakeholder groups that, along-
side regulators, payers, and clinicians, influence
access to and reimbursement for pharmaceutical
products. For example, patient pressure was a
key factor driving the decision of the UK Na-
tional Institute for Health and Clinical Excellence
(NICE) to approve Herceptin, a treatment for
early-stage breast cancer, for use by the UK Na-
tional Health Service.[1] Pharmaceutical compa-
nies operate in a highly competitive market and
are therefore aware of the need to communicate
patient-reported evidence of product benefits, spe-
cifically to regulatory and reimbursement author-
ities. Ensuring product success often warrants
companies to generate value propositions that go
beyond traditional biomedical safety and clinical
efficacy messages. One approach to achieve this is
by generating evidence on patients’ perspective of
treatment via standardized questionnaires known
as patient-reported outcomes (PROs). The pro-
cess has been largely industry led, and the flow
of information is unilinear, viz., from the patient
to industry and on to regulatory, payer, and clin-
ical stakeholders. However, in recent years, a new
concept has arisen that brings about a funda-
mental change in the information-exchange pro-
cess. Patients are increasingly using the Internet
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to retrieve and exchange health-related informa-
tion. In particular, patients are using web-based
social networking sites to share and compare their
experiences and satisfaction with pharmaceutical
treatments. It is likely that this new information-
exchange phenomenon will increasingly influence
patients’ decisions to seek, comply with, or re-
quest changes to their pharmaceutical therapies.
Although the pharmaceutical industry is be-
coming increasingly aware of the potential for
listening to and liaising with patients via the new
digital media, the information should not be con-
fused with PROs. Instead, a new term has been
recommended to describe the information col-
lected through the social web: patient-reported
information (PRI). New technologies and social
norms will possibly mean that, in time, gathered
data will yield new insights into the pathways of dis-
ease,medicines, and thewaymedicines are delivered.
We seek to distinguish PRIs fromPROs and discuss
some of the challenges that many stakeholders
face in closely listening to patients’ voices.
1. Patient-Reported Outcomes
and Information: Clarifying the
Terminology
Patients’ views on the effectiveness, or other-
wise, of pharmaceutical products are commonly
collected in clinical trials or observational trials
via PROmeasures. PRO is an umbrella term that
covers a range of potential measurement endpoints,
but is used specifically to refer to outcomes col-
lected directly from the patient, without interpre-
tation by clinicians or others.[2-4] The term PRO
was coined to avoid confusion in the regulatory
process regarding the different types of outcome
data collected as part of clinical trials.[5] PROs
may include measures of symptoms, activity limi-
tations, health status, quality of life (QOL) and
health-related QOL.[2,6] More recently, PROs have
also been used in clinical trials to evaluate patient
satisfaction, compliance, and treatment preferences.
All of these have potential value, provided the ap-
propriate outcomemeasure is selected to address the
needs of the trial and provided the data are collected
using high-quality questionnaire scales that are ap-
propriate for the patient population.[7]
PROs are commonly used in clinical trials to
capture patients’ voices in a structuredmanner using
validated questionnaires. PROs provide quanti-
tative data, that is, patient responses in terms of
a score (or scores) that allows investigators to
measure any change in the endpoint(s) assessed
following treatment, from a patient’s perspective.
Thus, they provide a means of quantifying qual-
itative information. In many conditions, such as
irritable bowel syndrome, migraine, and pain,
PROs may be used as the primary trial endpoint.
However, PROs are more commonly used as sec-
ondary endpoints that provide important sup-
portive evidence on treatment effects. As such,
they are often viewed as an ‘added extra’, pro-
viding supporting data to supplement traditional
biomedical indicators. The use of such outcomes
is particularly common among trials on products
developed to treat chronic, disabling conditions,
wherein the treatment goal is not to cure but to
ameliorate symptoms, facilitate functioning, or,
ultimately, to improve QOL. In such cases, pa-
tient-reported evidence is increasingly viewed as
an essential complement to traditional clinical
evidence for establishing a product’s competitive
advantage in the marketplace.[8]
Regulatory authorities commonly expect to
see evidence of the patient-reported benefits of
new treatments in dossiers submitted for the li-
censing of new drugs. Indeed, many clinical guid-
ance documents issued by regulatory authorities
mandate the inclusion of PRO data for clinical
trials.[9] Similarly, reimbursement authorities in
Canada, Australia, and many parts of Europe
include patient perspectives as part of their eval-
uation process.[10] For example, NICE in the UK
has recommended patient scores on the QoL-
AGHDA (a PRO scale for evaluating the QOL in
Adult GrowthHormoneDeficiency) as one of three
criteria for judging patient suitability for treatment
with recombinant human growth hormone.[11,12]
Clearly, PROs present a valuable means of
communicating patient-perceived benefits of treat-
ment to key stakeholders. However, in order to
differentiate their products, pharmaceutical com-
panies are increasingly recognizing the need to
supplement this by communicating the patient-
reported effects of drug therapies through what
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may be described as ‘patient-reported informa-
tion.’ Although PRI as a concept is not entirely
novel (a Google search on ‘patient reported in-
formation’ between 1 January 2010 and 18 June
2010 yielded 63 results), it has yet to be ad-
equately defined. There are examples where PRO
and PRI were used as interchangeable terms on
the Internet. However, PRI can be defined as in-
formation reported by patients relating to their
experience of disease and its treatment. PRO
connotes a concise and quantifiable means of
measuring clearly defined concepts, whereas PRI
constitutes qualitative information relating to
illness and treatment that exists outside the clin-
ical trials process. Although PRImay be collected
by the pharmaceutical industry via targeted re-
search, more often it is generated directly by
patients (or their caregivers), unprompted, via
social networking sites on the web. Unlike PRO
data, PRI data are not confined to the unilinear
model of information exchange. Instead, PRI
information is exchanged between many stake-
holders. In some cases this information can be
amplified and organized in an emergent manner.
Thus, the social web has the property of dis-
tributed cognition. These stories exist as micro-
narratives unconstrained by questionnaires and
hence are spontaneous. Furthermore, thesemicro-
narratives may be accessed in a variety of forms
directly, and they also have the property of inter-
acting with each other. Therefore, this system is
best described as a complex adaptive system and
its further understanding may require an under-
standing of theories of complex systems.[13]
PRIs represent a quandary for regulatory bodies
and other decision makers. On one hand, it pro-
vides an opportunity to listen to and enter into
dialogue with patients regarding their perception
of product benefits. On the other hand, it raises
the problem of ensuring that the insights created
have a robust and scientific methodology. PRIs
can provide valuable information on the key
areas of disease impact from a patient perspec-
tive. For example, patients with epilepsy reporting
on the PatientsLikeMe website[14] list problems
with memory, concentration, and fatigue as their
key areas of symptom impact. However, even a
cursory examination of patient comments on this
site highlights the wider impact of the condition
on QOL, with patients discussing issues such as
embarrassment (due to stigma) and the corre-
sponding impact on closeness and quality of
friendships. Such information can, in turn, be
used to inform on the most useful concepts for
measurement by PRO scales in clinical trials. In
the example of epilepsy, a study of PRIs could
reinforce the value of assessing both executive
function and QOL.[15] Furthermore, such data may
substantiate the justification of measuring such
constructs in discussion with regulatory and re-
imbursement authorities. Similarly, in consider-
ing existing PROs for clinical trials, an assessment
of PRIs can be used to provide further evidence
of the content validity of such scales for the target
patient group.
2. The Historical Relationship between
the Patient and Industry
The value of PRO data to the industry has
historically been viewed largely in terms of their
potential for securing regulatory claims and in
providing supporting arguments for product pro-
motion and reimbursement. In addition, there
may be patient-reported data that are included in
publications that could indeed enhance and am-
plify conversations within the social web. How-
ever, regulation decrees that manufacturers have
no recourse to comment on these, as any com-
mentary could be viewed as ‘off-label promo-
tion’. Consequently, the potential added value of
the wealth of PRO data currently collected and
held by the industry remains largely unrecognized,
overlooked and, ultimately, under-utilized. How-
ever, the PRO data that are generated by the
industry is often reported independently in the
social web. These data represent a valuable resource
that can be used to communicate patient-perceived
benefits of products to all key stakeholders, namely
payers, clinicians, patients, and regulators.
3. The Rise of the Empowered Patient
Consumers are increasingly engaging in a dia-
logue with providers regarding the services they
receive. Many seemingly complex products and
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services have been rendered comprehensible to
the lay consumer as a result of information avail-
able across a plethora of websites. Although con-
sumers are interacting in a transparent manner
on the social web, health and healthcare systems
have properties that are different from other
consumer goods, not least because they relate to
what are often intensely private issues. Further-
more, the consulting room has historically been
neither a democratic nor a transparent forum.
Until recently, patients presenting to healthcare
professionals have been, by tacit, mutual consent,
expected to provide sufficient information re-
garding their symptoms to inform their doctor’s
diagnosis, but only at the healthcare professional’s
request. A consultation may be defined as a dia-
logue only in the sense that both the parties may
have spoken, with the information leading to diag-
nosis having been elicited reactively, with the
doctor questioning and the patient contributing
only when asked to do so. However, patients have
always spoken about their condition, sometimes
as part of their coping strategy. New technologies
allow patients to not only find out about their
condition but also to interact and discuss their ex-
perience with other patients and patient groups.[16]
Within the context of what now may perhaps
be considered ‘mainstream’ social media sites, rich
patient-reported narratives are encountered not
only as textual status updates on microblogging
platforms such as Twitter or social networks such
as Facebook, but also as videos on YouTube, as
well as via patient blogs, patient forums, and
patient communities. Due to its ubiquity, fluidity,
and sheer volume, the notion that a ‘complete’ set
of PRI may be captured in some way is a chi-
merical one. Yet observers must take pleasure
from, rather than find frustration in, the fact that
patients will comment where they wish, when
they wish, and in the manner of their choosing.
Again, since many of the face-to-face discus-
sions of patient groups in the past are now codi-
fied on the social web (written down, achievable,
and searchable), individual data about experiences
hold greater value, especially when aggregated
and even clustered to provide new insights. Un-
surprisingly, the increasing use of the Internet to
expedite access to data on all health-related sub-
jects by patients and healthcare professionals is
‘‘redefining the roles of patient and physician.’’[17]
This reorientation has led an increasing number
of patients to expect that the consulting room will
be democratized: the monologue will become dia-
logue, the patient will be empowered to partic-
ipate proactively, and the opinion of each party
will be listened to and respected by the other.
Patients have found their own solutions to this
asymmetry of information, driving out complexity
through their commitment to transparency. Pa-
tient advocacy groups, patient communities, and
individual patient bloggers who self-identify as
‘e-patients’ (where the ‘e’ stands for ‘empowered’
rather than ‘electronic’) consider themselves to be
‘equipped, enabled, empowered, and engaged in
their health and healthcare decisions’, as well as
‘educated about the evidence’.[18,19] They deport
themselves online and in person with confidence
on the basis that, at least for them, this egalitarian
ideal is already a reality within the online envi-
ronments within which they connect, converse,
and collaborate.
4. The Future Potential of Industry-Patient
Communications
The challenge for the pharmaceutical industry is
to identify the most effective means of communicat-
ing patients’ perceptions of treatment benefits to the
different stakeholders in a changing technological
climate. This challenge comes in the wake of two key
revolutions: first, how companies market their pro-
ducts and second, how information is exchanged
and co-created in the age of the social web.
It is no longer accurate to use the future tense
when referring to the potential of the social web for
those seeking and sharing health information, ad-
vice, and support as this potential has already been
realized for many patients. Therefore, the pertinent
questions are whether healthcare professionals, reg-
ulators, and the pharmaceutical industry are able to
keep pace with this transition and whether they are
able to make the corresponding reorientation of
their perception to view patients as partners rather
than as subjects or as part of a target audience.
Patients may now have unprecedented access
to health information, but it is not certain that the
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information they may encounter will be relevant,
reliable, readily accessible, or intelligible to them.
It may prove a source of valuable facts if the pa-
tient is able to interpret its data, corroborate its
findings, and verify its authority, but in isolation
such data could just as easily prove to be a source
of misinformation, anxiety, or even danger. Pa-
tients also have the unprecedented ability to pub-
lish information unfettered and alongside a social
context that positively encourages sharing.
5. The New Terrain
This leads to a new terrain for the health con-
versation: one that is essentially flat, equitable, and
that strives to be democratic. While patients clearly
require information that is readily accessible, com-
prehensible, and from a trustworthy source, they
must also be afforded the opportunity to add
knowledge to the process. One approach to achieve
this is using the clinical trial process. It is con-
ceivable that information on drug effectiveness
could be pooled to the mutual benefit of all parties,
not only by combining evidence gathered as PRO
data from relevant clinical trials, but also through
channeling the rich narratives that are constructed
within multiple fora as PRI. These may be bold
aspirations, assuming, as they do, that the compa-
nies in question are aiming to align the future
growth of their enterprise with a commitment to the
social good in a substantive rather than a rhetorical
manner. The question for the whole health com-
munity is how to undertake the curation of this
discussion, that is, the collection and preservation
of PRI data (which, due to its nature, is often
transient), in an emergent scientific way in order to
make robust evidence-based decisions.
However, in order to expedite open, productive
engagement with the patient, with the intention
of registering, collating, and curating PRI, the
pharmaceutical industry faces at least two major
barriers. The first may be broadly described as
intercessionary, the second, contextual.
6. Challenges to the Industry
Externally, the pharmaceutical industry faces
an intercessionary barrier in the form of its re-
ception by the very patients with whom it wishes
to engage. While social media is trust-enabling, it
is also enabled by trust in the first instance. The
industry’s equivocal reputation in the eyes of the
public at large and its patient community in par-
ticular means that any correlation that may be
inferred between participation, visibility, and trans-
parency on the industry’s part in relation to the
amelioration of its reputation does not need to be
borne out in fact as a trust-generative benefit.
Furthermore, some in the health community
can be seen to have a mistrust of the social web as
‘social chit chat’ and a low grade of evidence.
Many healthcare sites do not feature tools al-
lowing the sort of one-click content redistribution
via status updating platforms such as Twitter,
social networks such as Facebook, or lifestream-
ing content consolidators such as Posterous that
encourage patients to report and share outcomes.
These sites are neither truly social web-enabled
nor likely to attract the enduring interest from
patient communities that will produce rich PRI
data. Furthermore, they are not always adequately
equipped or prepared to record and share data with
the community that creates it.
A further possible future contextual barrier may
coalesce around the overuse of a small number of
patient community sites on the basis that they are
perceived to be safe havens for patient-facing in-
itiatives. Vanguard enterprises such as the open
online community for organ transplant patients
established between PatientsLikeMe and Novartis
will perhaps encourage other companies to partner
with one of the many successful patient commu-
nities or patient-healthcare professional alliance sites
rather than to seek to augment the same platform
with further resources of their own suggestion.[20]
The final and perhaps the most problematic
contextual barrier for the industry is that patient
communities that appear to be the current leaders
in successfully collating PRI are also independent
of visible pharmaceutical industry involvement.
This does little to advance the case for the in-
dustry having a role in supporting communities
wherein PRI are recorded, measured, and as-
sessed against or even factored into PRO data.
An example of this is the open-source health re-
search resource CureTogether, which presents
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statistical information on symptoms, treatments,
causes, and related conditions by disease state
as an open informational resource. CureTogether
also affords registered members the opportunity
to submit their own experiences to each existing
survey category in addition to adding unlisted cri-
teria. For example, under the CureTogether entry
for chronic obstructive pulmonary disease, the most
frequently reported symptoms were shortness of
breath, tiring on simple tasks, wheezing, and sleep-
lessness. Bronchodilators, quitting smoking, al-
buterol, and corticosteroids were the treatments
deemed most effective by members. Second-hand
smoke, pollution, and smoking were considered
to be the causes of the condition by members.[21]
A signpost to the future of social web-facilitated,
appropriately weighted PRI collection and analy-
sis was erected with the publication on the Cure-
Together blog of the post 6 Surprisingly Effective
Treatments for Depression.[22] A CureTogether
community survey (n = 944) indicated that mem-
bers considered exercise, cognitive behavioral ther-
apy, and meditation as effective as well known
treatments for depression. The author chose to
interpret the data in order to foreground the fact
that it was less well known that some respondents
considered light therapy and massage therapy to
be more effective individually than a named
therapeutic in the treatment of depression. Cure-
Together members were left with the message that
they may wish to consider incorporating such pra-
ctices into their treatment pathways. Such PRIs can
be hypothesis generating and can provide useful
information in designing clinical studies.
It should be recognized that symptoms are
often self-evident to patients who exhibit and sub-
sequently live with them. Accordingly, patients
are more interested in learning about the impact
of their disease, the treatment pathways available
to them, and the associated evidence, as well as
the outcomes they may expect. The information
they elect to share with their peers within the
patient communities of the social web is rarely
available on product labels, which calls into
question the importance of PRO labels. Within
this context PRO labels may actually be deemed
too extrinsic and abstract to be of universal value.
While these PRI data may indeed be interesting,
they would fail at the first hurdle of many regu-
lators in their decision-making framework in
recommending that a product has such attrib-
utes. Further change would be necessary for reg-
ulators to evaluate and recommend the optimal
path an individual patient should take.
7. Conclusions
This article posits a new definition for ‘patient-
reported information.’ The exploration of PRI
can lead to new insights for patients into their
disease and medicines. However, there are many
hurdles to overcome before such data can be
successfully used by the pharmaceutical industry,
including the following.
 Social aspect: patients will continually need
and discuss information about their condition
and will also volunteer information in the
interest of the collective good.
 Technology aspect: it is likely that novel tech-
nologies will continually emerge to uncover
new insights from this collective wisdom.
 Regulation aspect: as the importance of PRI is
more widely recognized, agreements will be
needed to determine how these can be used
alongside and in a complementary fashion to
PROs and label claims. This involves both
promotional material from pharmaceutical pro-
fessionals to (and now from) healthcare pro-
fessionals, an aspect discussed extensively at a
recent US FDA meeting, and in a wider con-
sideration between how acting in a socially re-
sponsible way could yield new emerging insights
about treatment and disease. The concern is
that these approaches could be viewed as off-
label promotion by some stakeholders.
 Economic aspect: the value to patients of dis-
tributed knowledge, which will be made up of
the investment to collect and interpret these
data. New business models of collaboration
may result in the declining costs of being able
to perform these actions on the social web.
These challenges may ultimately culminate in
a cultural change whereby the pharmaceutical
industry will adopt a genuine service culture,
where a business and legal model enables it to
engage responsibly in the health conversation, as
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a trusted partner able to present patients with
clear and robust information to allow them to
make sense of, and make decisions regarding,
their healthcare. However, to do this, the indus-
try will need to engage in open, transparent con-
versations with patient communities within the
social web. The challenge is ongoing and needs
new leadership from all stakeholders.
Acknowledgments
No funding was provided for the writing of this
article. Mike Baldwin, a Senior Health Economist, and Ari
Gnanasakthy, a PRO expert, are employees of Novartis
Pharma. Andrew Spong is the Editorial Director of Nexus.
Andrew was remunerated by Novartis for thought leadership
adjacent to this work while being self-employed as a con-
sultant at STweM.com. Lynda Doward is the Director of Galen
Research Ltd, which has received financial recompense for pro-
vision of consultancy services to Novartis AG; specifically, ad-
vising on the use and selection of PRO scales in clinical trials.
References
1. Berg S. Herceptin: was patient power key? BBC News 2006
Jun 9 [online]. Available from URL: http://news.bbc.co.
uk/1/hi/health/5063352.stm [Accessed 2010 Oct 29]
2. Acquadro C, Berzon R, Dubois D, et al. Incorporating the
patient’s perspective into drug development and com-
munication: an ad hoc task force report on the Patient-
Reported Outcomes (PRO) Harmonization Group Meeting
at the Food and Drug Administration, February 16, 2001.
Value Health 2003; 5: 522-31
3. Burke LB, Kennedy DL, Miskala PH, et al. The use of
patient-reported outcome measures in the evaluation of
medical products for regulatory approval. Clin Pharmacol
Ther 2008 Aug; 84 (2): 281-3
4. European Medicines Agency. Committee for Medicinal
Products for Human use (CMHP). Reflection paper on the
regulatory guidance for the use of health-related quality of
life (HRQL) measures in the evaluation of medicinal
products. London: EMA, 2005 Jul 27. Doc. ref. EMEA/
CHMP/EWP/139391/2004
5. Burke L. Acceptable evidence for pharmaceutical advertis-
ing and labeling. Drug Information Association workshop
on Pharmacoeconomics and Quality of Life Labeling and
Marketing Claims; 2000 Oct 3; New Orleans (LA). Hor-
sham (PA): Drug Information Association, 2000
6. Doward LC, McKenna SP. Defining patient-reported out-
comes. Value Health 2004; 7 Suppl. 1: S4-8
7. Doward LC, Meads DM, Thorsen H. Requirements for
quality of life instruments in clinical research. Value Health
2004; 7 Suppl. 1: S13-6
8. Doward LC, Gnanasakthy A, Baker MG. Patient reported
outcomes: looking beyond the label claim. Health Qual
Life Outcomes 2010 Aug 20; 8: 89
9. Mordin M, Lewis S, Gnanasakthy A, et al. Patient-reported
outcomes in product development guidance [abstract no.
PMC21]. Value Health 2010; 13 (3): A17-8
10. Draborg E, Gyrd-Hansen D, Poulsen PB, et al. Interna-
tional comparison of the definition and the practical
application of health technology assessment. Int J Technol
Assess Health Care 2005; 21 (1): 89-95
11. Holmes SJ, McKenna SP, Doward LC, et al. Development
of a questionnaire to assess the quality of life of adults with
growth hormone deficiency. EndocrinolMetab 1995; 2: 63-9
12. National Institute for Health and Clinical Excellence. Human
growth hormone (somatropin) in adults with growth hor-
mone deficiency. Technology appraisal 64. London: NICE,
2003 Aug [online]. Available from URL: http://www.nice.
org.uk/nicemedia/pdf/TA64_HGHadults_fullguidance.pdf
[Accessed 2009 Nov 12]
13. Snowden DJ, Boone ME. A leader’s framework for decision
making. Harv Bus Rev 2007 Nov; 85 (11): 68-76, 149
14. PatientsLikeMe epilepsy community. What are patients
sharing? [online]. Available from URL: http://www.patients
likeme.com/epilepsy/community [Accessed 2010 Oct 18]
15. PatientsLikeMe. Manage your epilepsy like a PRO [online].
Available fromURL: http://blog.patientslikeme.com/2010/02/
11/manage-your-epilepsy-like-a-pro/ [Accessed 2010 Oct 18]
16. Hartzband P, Groopman J. Untangling the web: patients,
doctors and the internet. N Engl J Med 2010Mar; 362 (12):
1063-6
17. E-patients.net. About us [online]. Available from URL:
http://e-patients.net/about-e-patientsnet [Accessed 2010 Jul 23]
18. deBronkart D. EPatientDave [online]. Available fromURL:
http://twitter.com/ePatientDave/status/12703809401 [Ac-
cessed 2010 Jul 23]
19. Spong A. Patient community (curated list of sites) [online].
Available from URL: http://bit.ly/cNR5ho [Accessed 2010
Jul 23]
20. PatientsLikeMe collaborates with Novartis to create an
open online community for organ transplant recipients:
two new programs unveiled to help patients ‘give back’
[press release]. 2010 Mar 9 [online]. Available from URL:
http://bit.ly/eJhB4w [Accessed 2010 Dec 10]
21. CureTogether. Chronic obstructive pulmonary disease (sta-
tistics and survey) [online]. Available from URL: http://
www.curetogether.com/chronic-obstructive-pulmonary-
disease/symptoms [Accessed 2010 Apr 16]
22. Carmichael A. 6 surprisingly effective treatments for depres-
sion [online]. Available from URL: http://curetogether.
com/blog/2010/04/22/6-surprising-depression-treatments/
[Accessed 2010 Nov 2]
Correspondence: Mr Mike Baldwin, Novartis Horsham Re-
search Centre, Wimblehurst Road, Horsham, West Sussex,
RH12 5AB, UK.
E-mail: mike.baldwin@novartis.com
Patient-Reported Outcomes and Information 17
ª 2011 Adis Data Information BV. All rights reserved. Patient 2011; 4 (1)
